What will be the primary source of funding for the next phase of the Truveta Genome Project by end of 2025?
Government grant • 25%
Private investment • 25%
Pharmaceutical company • 25%
Crowdfunding • 25%
Official funding announcements from Truveta or participating entities
Truveta and 30 Health Systems Launch $320M Genome Project for 10 Million Volunteers
Jan 16, 2025, 04:47 PM
Truveta, in collaboration with 30 health systems across the United States, has launched the Truveta Genome Project, aiming to create the largest and most diverse database of genetic data. The project, which has received a $320 million investment from Regeneron, Illumina, and the participating health systems, including $119.5 million from Regeneron and $20 million from Illumina, will sequence the exomes of the first 10 million volunteers. Microsoft Azure will serve as the cloud provider for the project. This initiative is designed to accelerate personalized medicine and facilitate the discovery of new drugs by linking genetic data with de-identified medical records. The project's goal is to improve the understanding of genetic contributions to health and disease, potentially transforming healthcare from treating diseases to preventing them.
View original story
Regeneron • 25%
Other • 25%
Illumina • 25%
Truveta • 25%
Other • 25%
Private Investors • 25%
U.S. Government • 25%
International Organizations • 25%
Drug Discovery • 25%
Clinical Trials Optimization • 25%
Healthcare Delivery Improvement • 25%
Other • 25%
European • 25%
African • 25%
Asian • 25%
Other • 25%
City Budget • 25%
Private Investments • 25%
Federal Grants • 25%
State Funding • 25%
Bank Loans • 25%
Private Investors • 25%
Family and Friends • 25%
Venture Capital • 25%
Kleiner Perkins • 25%
General Catalyst • 25%
Other existing investor • 25%
A new investor • 25%
Global Fund • 25%
Other • 25%
Gilead Sciences • 25%
PEPFAR • 25%
More than $200 million • 25%
$100 million to $200 million • 25%
$50 million to $100 million • 25%
Less than $50 million • 25%
Less than $100 million • 25%
$100 million to $200 million • 25%
$200 million to $300 million • 25%
More than $300 million • 25%
Yes • 50%
No • 50%
Less than 35 • 25%
More than 45 • 25%
41 to 45 • 25%
35 to 40 • 25%